Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Padmaja Chaparala

Psychiatry Richmond, VA Medical Doctor

NPI 1366556334 CMS profile 61758

3212 Cutshaw Ave, Suite 303, Richmond, VA 23230

Open in the dashboard

General payments

$763

11 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Padmaja Chaparala of Richmond, VA is reported in the CMS Open Payments database as having received $763 across 11 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 67th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $247 2
2024 General $257 5
2023 General $42 2
2019 General $218 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Padmaja Chaparala
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Padmaja Chaparala were reported at $247. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Padmaja Chaparala Psychiatry median Middle half National median
2019 $218 $184 $59–$605 $163
2020 $0 $119 $36–$372 $114
2021 $0 $143 $43–$576 $132
2022 $0 $153 $50–$590 $149
2023 $42 $170 $56–$651 $160
2024 $257 $179 $57–$673 $164
2025 $247 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. ITI, Inc. $257 5 payments
  2. Neurocrine Biosciences, Inc. $218 2 payments
  3. Otsuka America Pharmaceutical, Inc. $140 2 payments
  4. Janssen Pharmaceuticals, Inc $125 1 payment
  5. BioXcel Therapeutics, Inc. $24 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $763 11 payments
Products named General payments · program years 2019–2025
  1. CAPLYTA $257 5 payments
  2. INGREZZA $218 2 payments
  3. ABILIFY MAINTENA $140 2 payments
  4. SPRAVATO $125 1 payment
  5. ABILIFY ASIMTUFII $122 1 payment
  6. IGALMI $24 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

418

Median for Psychiatry & Neurology: 100

Drug cost

$62,311

Median for Psychiatry & Neurology: $2,986

Branded share of claims

10.3%

Median for Psychiatry & Neurology: 16.2%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Risperidone Er Risperidone Microspheres Brand 27 $49,497
Paliperidone Er Paliperidone Brand 16 $7,949
Olanzapine Generic 97 $1,571
Haloperidol Generic 49 $737
Divalproex Sodium Generic 35 $695
Clozapine Generic 13 $568
Lorazepam Generic 83 $389
Clonazepam Generic 16 $356
Risperidone Generic 42 $309
Lithium Carbonate Generic 20 $150

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,755 Part D prescribers listed as Psychiatry & Neurology; they describe a distribution and say nothing about conduct.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
CAPLYTA
  • ITI, Inc. $257
$257 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

11 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record